Biopsy Procedure + Biospecimen Collection + Echocardiography Test + Multigated Acquisition Scan + Radiologic Imaging Procedure + PIDNARULEX + TRASTUZUMAB DERUXTECAN for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 22 Aug 2025: Trial registered, NCT07137416
  2. 6 Oct 2026: Trial started, NCT07137416

The trials

NCT07137416: Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer

State
Under way
Phase
Phase 1
People
36 planned
Started
6 Oct 2026
Primary completion
10 Jan 2028
Arms
Treatment (Pidnarulex, T-DXd)
Results
None posted
  1. 22 Aug 2025: Trial registered
  2. 6 Oct 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.